TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/ YAP pathway
Cancer Science · 2024
DOI: 10.1111/cas.16134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Bo Shu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Ribonucleoproteins, Signal Transduction. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan Provincial Natural Science Foundation of China, Changsha Municipal Natural Science Foundation.
Abstract (Originalsprache)
Liver cancer is the sixth most common cancer and the third leading cause of cancer‐related death globally. Despite efforts being made in last two decades in cancer diagnosis and treatment, the 5‐year survival rate of liver cancer remains extremely low. TRIM21 participates in cancer metabolism, glycolysis, immunity, chemosensitivity and metastasis by targeting various substrates for ubiquitination. TRIM21 serves as a prognosis marker for human hepatocellular carcinoma (HCC), but the mechanism by which TRIM21 regulates HCC tumorigenesis and progression remains elusive. In this study, we demonstrated that TRIM21 protein levels were elevated in human HCC. Elevated TRIM21 expression was associated with HCC progression and poor survival. Knockdown of TRIM21 in HCC cell lines significantly impaired cell growth and metastasis and enhanced sorafenib‐induced toxicity. Mechanistically, we found that knockdown of TRIM21 resulted in cytosolic translocation and inactivation of YAP. At the molecular level, we further identified that TRIM21 interacted and induced ubiquitination of MST1, which resulted in MST1 degradation and YAP activation. Knockdown of MST1 or overexpression of YAP reversed TRIM21 knockdown‐induced impairment of HCC growth and chemosensitivity. Taken together, the current study demonstrates a novel mechanism that regulates the Hippo pathway and reveals TRM21 as a critical factor that promotes growth and chemoresistance in human HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Surgical Operation, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Neurosurgery, Brain Hospital of Hunan Province (The Second People's Hospital of Human Province), Changsha, Hunan, China.
- Department of Pharmacy, Hunan Normal University School of Medicine, Changsha, Hunan, China.
Förderung
- Hunan Provincial Natural Science Foundation of China
- Changsha Municipal Natural Science Foundation
Zitieren
APA
Shu, B., Zhou, Y., Lei, G., Peng, Y., Ding, C., Li, Z., & He, C. (2024). TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/ YAP pathway. Cancer Science. https://doi.org/10.1111/cas.16134
Vancouver
Shu B, Zhou Y, Lei G, Peng Y, Ding C, Li Z, et al. TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/ YAP pathway. Cancer Science. 2024. doi:10.1111/cas.16134
BibTeX
@article{Shu2024,
author = {Shu, Bo and Zhou, Yingxia and Lei, Guoqiong and Peng, Yu and Ding, Cong and Li, Zhuan and He, Chao},
title = {TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/ YAP pathway},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16134}
}
EUVIMED